162 related articles for article (PubMed ID: 17076527)
1. Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma.
Cerruto CA; Brun EA; Chang D; Sugarbaker PH
Arch Pathol Lab Med; 2006 Nov; 130(11):1654-61. PubMed ID: 17076527
[TBL] [Abstract][Full Text] [Related]
2. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma.
Yan TD; Brun EA; Cerruto CA; Haveric N; Chang D; Sugarbaker PH
Ann Surg Oncol; 2007 Jan; 14(1):41-9. PubMed ID: 17039392
[TBL] [Abstract][Full Text] [Related]
3. Significance of lymph node metastasis in patients with diffuse malignant peritoneal mesothelioma.
Yan TD; Yoo D; Sugarbaker PH
Eur J Surg Oncol; 2006 Nov; 32(9):948-53. PubMed ID: 16806796
[TBL] [Abstract][Full Text] [Related]
4. [Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy].
Passot G; Cotte E; Brigand C; Beaujard AC; Isaac S; Gilly FN; Glehen O
J Chir (Paris); 2008; 145(5):447-53. PubMed ID: 19106865
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis.
Hubert J; Thiboutot E; Dubé P; Cloutier AS; Drolet P; Sideris L
Surg Oncol; 2015 Mar; 24(1):41-6. PubMed ID: 25680983
[TBL] [Abstract][Full Text] [Related]
6. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*.
Yan TD; Deraco M; Elias D; Glehen O; Levine EA; Moran BJ; Morris DL; Chua TC; Piso P; Sugarbaker PH;
Cancer; 2011 May; 117(9):1855-63. PubMed ID: 21509762
[TBL] [Abstract][Full Text] [Related]
7. The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Deraco M; Baratti D; Hutanu I; Bertuli R; Kusamura S
Ann Surg Oncol; 2013 Apr; 20(4):1093-100. PubMed ID: 23456386
[TBL] [Abstract][Full Text] [Related]
8. [Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia].
Gómez Portilla A; Cendoya I; Muriel J; Olabarria I; Guede N; Moraza N; Fernández E; Martínez de Lecea C; Magrach L; Martín E; Romero E; Aguado I; Valdovinos M; Larrabide I
Cir Esp; 2007 Feb; 81(2):82-6. PubMed ID: 17306123
[TBL] [Abstract][Full Text] [Related]
9. Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.
Chapel DB; Schulte JJ; Absenger G; Attanoos R; Brcic L; Butnor KJ; Chirieac L; Churg A; Galateau-Sallé F; Hiroshima K; Hung YP; Kindler H; Krausz T; Marchevsky A; Mino-Kenudson M; Mueller J; Nabeshima K; Turaga K; Walts AE; Husain AN
Mod Pathol; 2021 Feb; 34(2):380-395. PubMed ID: 33060816
[TBL] [Abstract][Full Text] [Related]
10. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
[TBL] [Abstract][Full Text] [Related]
11. Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
Sugarbaker PH; Chang D
Eur J Surg Oncol; 2017 Jul; 43(7):1228-1235. PubMed ID: 28189456
[TBL] [Abstract][Full Text] [Related]
12. Five reasons why cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy must be regarded as the new standard of care for diffuse malignant peritoneal mesotheliomia [corrected].
Sugarbaker PH
Ann Surg Oncol; 2010 Jun; 17(6):1710-2; author reply 1713-4. PubMed ID: 20354799
[No Abstract] [Full Text] [Related]
13. Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study.
Brigand C; Monneuse O; Mohamed F; Sayag-Beaujard AC; Isaac S; Gilly FN; Glehen O
Ann Surg Oncol; 2006 Mar; 13(3):405-12. PubMed ID: 16485159
[TBL] [Abstract][Full Text] [Related]
14. Results of treatment of 33 patients with peritoneal mesothelioma.
Sebbag G; Yan H; Shmookler BM; Chang D; Sugarbaker PH
Br J Surg; 2000 Nov; 87(11):1587-93. PubMed ID: 11091251
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival.
Gilani SNS; Mehta A; Garcia-Fadrique A; Rowaiye B; Jenei V; Dayal S; Chandrakumaran K; Carr N; Mohamed F; Cecil T; Moran B
Int J Hyperthermia; 2018 Aug; 34(5):578-584. PubMed ID: 29431036
[TBL] [Abstract][Full Text] [Related]
16. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC.
Robella M; Vaira M; Mellano A; Marsanic P; Cinquegrana A; Borsano A; Barbera M; Caneparo A; Siatis D; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):9-15. PubMed ID: 24675242
[TBL] [Abstract][Full Text] [Related]
17. Combined grade and nuclear grade are prognosis predictors of epithelioid malignant peritoneal mesothelioma: a multi-institutional retrospective study.
Benzerdjeb N; Dartigues P; Kepenekian V; Valmary-Degano S; Mery E; Averous G; Chevallier A; Laverriere MH; Villa I; Sallé FG; Villeneuve L; Glehen O; Isaac S; Hommell-Fontaine J;
Virchows Arch; 2021 Nov; 479(5):927-936. PubMed ID: 34169365
[TBL] [Abstract][Full Text] [Related]
18. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
Deraco M; Nonaka D; Baratti D; Casali P; Rosai J; Younan R; Salvatore A; Cabras Ad AD; Kusamura S
Ann Surg Oncol; 2006 Feb; 13(2):229-37. PubMed ID: 16444562
[TBL] [Abstract][Full Text] [Related]
19. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.
Hommell-Fontaine J; Isaac S; Passot G; Decullier E; Traverse-Glehen A; Cotte E; You B; Mohamed F; Gilly FN; Glehen O; Berger F
Ann Surg Oncol; 2013 Nov; 20(12):3892-8. PubMed ID: 23800898
[TBL] [Abstract][Full Text] [Related]
20. Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients.
Liu S; Staats P; Lee M; Alexander HR; Burke AP
Pathology; 2014 Dec; 46(7):604-9. PubMed ID: 25393250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]